The Epstein-Barr virus is one of the most common and persistent human viruses in the world, according to the CDC.

Toxoplasma gondii is a widespread parasite responsible for toxoplasmosis, an infection that often lacks clear symptoms but ...

Gammagard Liquid ERC is a ready-to-use formulation with low IgA content designed to ease administration burden by removing the need to reconstitute.

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with ...

The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies spec ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and BHV-1300, at its 2025 R&D Day in New Haven. BHV-1400, a first-in-class TRAP ...

IgA Nephropathy (IgAN) is a common kidney disease and a main cause of kidney failure and chronic kidney disease. Read more about its symptoms, causes, risk factors, complications and treatments.

Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world ...

The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company ...